GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC lifted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 165.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,538 shares of the company’s stock after acquiring an additional 11,548 shares during the period. EntryPoint Capital LLC’s holdings in GoodRx were worth $132,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GDRX. Citigroup Inc. increased its holdings in shares of GoodRx by 301.7% in the third quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock valued at $45,000 after purchasing an additional 6,006 shares during the period. Gerber LLC purchased a new position in GoodRx during the 4th quarter worth approximately $75,000. Schnieders Capital Management LLC acquired a new stake in GoodRx during the 1st quarter valued at approximately $93,000. Innealta Capital LLC purchased a new stake in shares of GoodRx in the 4th quarter valued at $91,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of GoodRx by 82.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,006 shares of the company’s stock worth $107,000 after acquiring an additional 7,244 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Trading Up 0.7 %

Shares of GDRX stock traded up $0.06 on Friday, hitting $8.80. 128,713 shares of the stock traded hands, compared to its average volume of 1,423,171. The firm’s 50-day moving average price is $8.03 and its two-hundred day moving average price is $7.22. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. The stock has a market capitalization of $3.30 billion, a PE ratio of -887.00, a PEG ratio of 4.18 and a beta of 1.39. GoodRx Holdings, Inc. has a twelve month low of $4.14 and a twelve month high of $9.37.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. The firm had revenue of $197.88 million for the quarter, compared to analyst estimates of $196.20 million. As a group, analysts anticipate that GoodRx Holdings, Inc. will post 0.17 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Royal Bank of Canada raised shares of GoodRx from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $8.00 to $10.00 in a report on Thursday, May 23rd. Barclays lifted their price target on GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research note on Monday, May 20th. Morgan Stanley increased their target price on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research report on Monday, June 10th. TD Cowen boosted their price target on shares of GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th. Finally, Raymond James raised shares of GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a report on Thursday, May 16th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.32.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.